Literature DB >> 17632511

Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.

Cristina Sobacchi1, Annalisa Frattini, Matteo M Guerrini, Mario Abinun, Alessandra Pangrazio, Lucia Susani, Robbert Bredius, Grazia Mancini, Andrew Cant, Nick Bishop, Peter Grabowski, Andrea Del Fattore, Chiara Messina, Gabriella Errigo, Fraser P Coxon, Debbie I Scott, Anna Teti, Michael J Rogers, Paolo Vezzoni, Anna Villa, Miep H Helfrich.   

Abstract

Autosomal recessive osteopetrosis is usually associated with normal or elevated numbers of nonfunctional osteoclasts. Here we report mutations in the gene encoding RANKL (receptor activator of nuclear factor-KB ligand) in six individuals with autosomal recessive osteopetrosis whose bone biopsy specimens lacked osteoclasts. These individuals did not show any obvious defects in immunological parameters and could not be cured by hematopoietic stem cell transplantation; however, exogenous RANKL induced formation of functional osteoclasts from their monocytes, suggesting that they could, theoretically, benefit from exogenous RANKL administration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17632511     DOI: 10.1038/ng2076

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  111 in total

Review 1.  New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.

Authors:  J C Crockett; D J Mellis; D I Scott; M H Helfrich
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

Review 2.  Signaling networks that control the lineage commitment and differentiation of bone cells.

Authors:  Carrie S Soltanoff; Shuying Yang; Wei Chen; Yi-Ping Li
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

3.  Osteoclasts and hematopoiesis.

Authors:  Anna Teti
Journal:  Bonekey Rep       Date:  2012-03-28

4.  Panostotic expansile bone disease with massive jaw tumor formation and a novel mutation in the signal peptide of RANK.

Authors:  Anne L Schafer; Steven Mumm; Ivan El-Sayed; William H McAlister; Andrew E Horvai; Andrea M Tom; Edward C Hsiao; Frederick V Schaefer; Michael T Collins; Mark S Anderson; Michael P Whyte; Dolores M Shoback
Journal:  J Bone Miner Res       Date:  2014-04       Impact factor: 6.741

5.  Novel mutation of TCIRG1 and clinical pictures of two infantile malignant osteopetrosis patients.

Authors:  Ping Yuan; Zhihui Yue; Liangzhong Sun; Weijun Huang; Bin Hu; Zhiyun Yang; Yuelin Hu; Hua Xiao; Hui Shi; Qing Zhou; Yiming Wang
Journal:  J Bone Miner Metab       Date:  2010-11-02       Impact factor: 2.626

Review 6.  Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate.

Authors:  Cristina Sobacchi; Eleonora Palagano; Anna Villa; Ciro Menale
Journal:  Front Bioeng Biotechnol       Date:  2017-05-17

Review 7.  Nuclear receptors in bone physiology and diseases.

Authors:  Yuuki Imai; Min-Young Youn; Kazuki Inoue; Ichiro Takada; Alexander Kouzmenko; Shigeaki Kato
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

8.  Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency.

Authors:  Jinhu Xiong; Marilina Piemontese; Jeff D Thostenson; Robert S Weinstein; Stavros C Manolagas; Charles A O'Brien
Journal:  Bone       Date:  2014-06-14       Impact factor: 4.398

9.  An enhancer 20 kilobases upstream of the human receptor activator of nuclear factor-kappaB ligand gene mediates dominant activation by 1,25-dihydroxyvitamin D3.

Authors:  Robert D Nerenz; Melissa L Martowicz; J Wesley Pike
Journal:  Mol Endocrinol       Date:  2008-01-17

Review 10.  Advances in osteoclast biology resulting from the study of osteopetrotic mutations.

Authors:  T Segovia-Silvestre; A V Neutzsky-Wulff; M G Sorensen; C Christiansen; J Bollerslev; M A Karsdal; K Henriksen
Journal:  Hum Genet       Date:  2008-11-06       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.